Long-term follow-up of a population based cohort with monoclonal proteinaemia

British Journal of Haematology

Volumn 144, Issue 2, 2009, Pages 176-184

  Schaar, Cees G ^b   Le Cessie, Saskia ^c,d   Snijder, Simone ^d   Franck, Paul F H ^e   Wijermans, Pierre W ^e   Ong, Cisca ^f   Kluin Nelemans, Hanneke ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b GELRE HOSPITALS   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Integraal Kankercentrum West   (Netherlands)

^e HAGA HOSPITAL   (Netherlands)

^f MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

Malignant transformation; Monoclonal gammopathy of undetermined significance; Monoclonal proteinaemia; Survival

Indexed keywords

CREATININE; HEMOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; M PROTEIN; SERUM ALBUMIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD PROTEIN DISORDER; BONE MARROW EXAMINATION; BONE RADIOGRAPHY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN TISSUE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MONOCLONAL PROTEINAEMIA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELOMA PROTEINS; PARAPROTEINEMIAS; PROSPECTIVE STUDIES; PROTEIN ISOFORMS; RISK; SURVIVAL RATE; YOUNG ADULT;

EID: 58149084617     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07423.x     Document Type: Article

References (34)

1. Anagnostopoulos, A., Evangelopoulou, A., Sotou, D., Gika, D., Mitsoubounas, M.A. Dimopoulos, M.A. (2002) Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece. Annals of Hematology, 81, 357 361.
2. Axelsson, U. (1986) A 20-year follow-up study of 64 subjects with M-components. Acta Medica Scandinavica, 219, 519 522.
3. Axelsson, U., Bachmann, R. Hallen, J. (1966) Frequency of pathological proteins (M-components) om 6,995 sera from an adult population. Acta Medica Scandinavica, 179, 235 247.
4. Baldini, L., Guffanti, A., Cesana, B.M., Colombi, M., Chiorboli, O., Damilano, I. Maiolo, A.T. (1996) Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. Blood, 87, 912 918.
5. Blade, J., Lopez-Guillermo, A., Rozman, C., Cervantes, F., Salgado, C., Aguilar, J.L., Vives-Corrons, J.L. Montserrat, E. (1992) Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. British Journal of Haematology, 81, 391 394.
6. Cesana, C., Klersy, C., Barbarano, L., Nosari, A.M., Crugnola, M., Pungolino, E., Gargantini, L., Granata, S., Valentini, M. Morra, E. (2002) Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Journal of Clinical Oncology, 20, 1625 1634.
7. Colls, B.M. (1999) Monoclonal gammopathy of undetermined significance (MGUS) - 31 year follow up of a community study. Australian and New Zealand Journal of Medicine, 29, 500 504.
8. Di Mario, D.M.A., Rossi, E., Zini, G. De Stefano, V. (2002) Malignant transformation of monoclonal gammopathies: a retrospective study. The Hematology Journal, 3, 381 381.
9. van de Donk, N., de Weerdt, O., Eurelings, M., Bloem, A. Lokhorst, H.M. (2001) Malignant transformation of monoclonal gammopathy of undetermined signifance: cumulative incidence and prognostic factors. Leukemia and Lymphoma, 42, 609 618.
10. Giraldo, M.P., Rubio-Felix, D., Perella, M., Gracia, J.A., Bergua, J.M. Giralt, M. (1991) Monoclonal gammopathies of undetermined significance. Clinical course and biological aspects of 397 cases Gammapatias monoclonales de significado indeterminado. Aspectos clinicos, biologicos y evolutivos de 397 casos. Sangre, 36, 377 382.
11. Gregersen, H., Salling Ibsen, J., Mellemkjaer, L., Dahlerup, J.F. Olsen, J.H. (2001a) Mortality and causes of death in patients with moclonal gammopathy of unknown significance. British Journal of Haematology, 112, 353 357.
12. Gregersen, H., Mellemkjaer, L., Salling, I.J., Dahlerup, J.F., Thomassen, L. Sorensen, H.T. (2001b) The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. Haematologica, 86, 1172 1179.
13. Greipp, P.R., San, M.J., Durie, B.G., Crowley, J.J., Barlogie, B., Blade, J., Boccadoro, M., Child, J.A., vet-Loiseau, H., Kyle, R.A., Lahuerta, J.J., Ludwig, H., Morgan, G., Powles, R., Shimizu, K., Shustik, C., Sonneveld, P., Tosi, P., Turesson, I. Westin, J. (2005) International staging system for multiple myeloma. Journal of Clinical Oncology, 23, 3412 3420.
14. Hakulinen, T. (1982) Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics, 38, 933 942.
15. Hallen, J. (1966) Discrete gammaglobulin (M-) components in serum. Clinical study of 150 subjects without myelomatosis. Acta Medica Scandinavica, 462, 1 127.
16. International Myeloma Working Group 2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. British Journal of Haematology, 121, 749 757.
17. Kyle, R.A. (1993) "Benign" monoclonal gammopathy - after 20 to 35 years of follow-up. Mayo Clinic Proceedings, 68, 26 36.
18. Kyle, R.A., Therneau, T.M., Rajkumar, S.V., Offord, J.R., Larson, D.R., Plevak, M.F. Melton, L.J. (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. New England Journal of Medicine, 346, 564 569.
19. Kyle, R.A., Therneau, T.M., Rajkumar, S.V., Larson, D.R., Plevak, M.F., Offord, J.R., Dispenzieri, A., Katzmann, J.A. Melton, III., L.J. (2006) Prevalence of monoclonal gammopathy of undetermined significance. New England Journal of Medicine, 354, 1362 1369.
20. Lichtman, M.A., Beutler, E., Lichtman, M.A., Coller, B.S., Kipps, T.J. Seligsohn, U. (2001) Essential monoclonal gammopathy. In : Williams Hematology, Vol. 6 (ed. by E. Beutler, M.A. Lichtman, B.S. Coller, T.J. Kipps, W.J. Williams U. Seligsohn pp. 1271 1277. Mc Graw Hill Inc, Health Professions Division, New York.
21. Ong, F., Hermans, J., Noordijk, E.M. Kluin-Nelemans, J.C. (1995a) Is the Durie and Salmon diagnostic classification system for plasma cell dyscrasias still the best choice? Application of three classification systems to a large population-based registry of paraproteinemia and multiple myeloma. Annals of Hematology, 70, 19 24.
22. Ong, F., Hermans, J., Noordijk, E.M., Wijermans, P.W. Kluin-Nelemans, J.C. (1995b) Presenting signs and symptoms in multiple myeloma: high percentages of stage III among patients without apparent myeloma-associated symptoms. Annals of Hematology, 70, 149 152.
23. Ong, F., Kaiser, U., Seelen, P.J., Hermans, J., Wijermans, P.W., de Kieviet, W., Jaques, G. Kluin-Nelemans, J.C. (1996) Serum neural cell adhesion molecule differentiates multiple myeloma from paraproteinemias due to other causes. Blood, 87, 712 716.
24. Ong, F., Hermans, J., Noordijk, E.M., de Kieviet, W., Seelen, P.J., Wijermans, P.W. Kluin-Nelemans, J.C. (1997a) Development of a "Myeloma Risk Score" using a population-based registry on paraproteinemia and myeloma. Leukemia & Lymphoma, 27, 495 501.
25. Ong, F., Hermans, J., Noordijk, E.M., Wijermans, P.W., Seelen, P.J., de Kieviet, W., Gerrits, W.B., Kluin, P.M. Kluin-Nelemans, J.C. (1997b) A population-based registry on paraproteinaemia in The Netherlands. Comprehensive Cancer Centre West, Leiden, The Netherlands. British Journal of Haematology, 99, 914 920.
26. Pasqualetti, P., Festuccia, V., Collacciani, A. Casale, R. (1997) The natural history of monoclonal gammopathy of undetermined significance. A 5- to 20-year follow-up of 263 cases. Acta Haematologica, 97, 174 179.
27. van de Poel, M.H.W., Coebergh, J.W.W. Hillen, H.F.P. (1995) Malignant transformation of monoclonal gammopathy of undetermined significance among out-patients of a community hospital in southeastern Netherlands. British Journal of Haematology, 91, 121 125.
28. Rajkumar, S.V., Kyle, R.A., Therneau, T.M., Melton Iii, L.J., Bradwell, A.R., Clark, R.J., Larson, D.R., Plevak, M.F., Dispenzieri, A. Katzmann, J.A. (2005) Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS). Blood, 106, 812 817.
29. Saleun, J.P., Vicariot, M., Deroff, P. Morin, J.F. (1982) Monoclonal gammopathies in the adult population of Finestäre, France. Journal of Clinical Pathology, 35, 63 68.
30. Satagopan, J.M., Ben-Porat, L., Berwick, M., Robson, M., Kutler, D. Auerbach, A.D. (2004) A note on competing risks in survival data analysis. British Journal of Cancer, 91, 1229 1235.
31. Schaar, C.G., Kaiser, U., Snijder, S., Ong, F., Hermans, J., Franck, P.F. Kluin-Nelemans, J.C. (1999) Serum interleukin-6 has no discriminatory role in paraproteinaemia nor a prognostic role in multiple myeloma. British Journal of Haematology, 107, 132 138.
32. Schaar, C.G., Snijder, S., Oostindier, M.J., Rosendaal, F.R., Willemze, R. Kluin-Nelemans, J.C. (2004) Monoclonal proteinaemia and solid tumours. European Journal of Cancer, 40, 1539 1544.
33. Veneri, D., Aqel, H., Franchini, M., Krampera, M., Zanotti, R. Pizzolo, G. (2004) Malignant evolution of monclonal gammopathy of unknown significance: an analysis of 633 consecutive cases with a long term follow-up. Haematologica, 89, 876 877.
34. Vuckovic, J., Ilic, A., Knezevic, N., Marinkovic, M., Zemunik, T. Dubravcic, M. (1997) Prognosis in monoclonal gammopathy of undetermined significance. British Journal of Haematology, 97, 649 651.